Hydroxychloroquin (Plaquenil) treatment of recurrent pregnancy loss – a randomized, double blinded, placebo controlled study - Hydroxychloroquin treatment of abortus habitualis

Henriette Svarre Nielsen0 个研究点目标入组 186 人开始时间: 2017年1月26日最近更新: 2024年8月5日

适应症

试验速览

暂无简介。

•>3 recurrent subsequent spontaneous pregnancy losses or 3 recurrent subsequent spontaneous pregnancy losses of which one is a second trimester loss.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 186
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1) Age below 18 or above 40 at the time of achieved pregnancy
•2) Significant uterine abnormalities diagnosed by hysterosalpingography/hysteroscopy/hydrosonography.
•3) Significant chromosome abnormalia (especially tranlocations) in the couple
•4) Menstruation cycle < 23 days or > 35 days
•5) Lupusanticoagulans or IgG anticardiolipinantibody concentration =40 GPL kU/l or plasma homocystein =25 mikrogr./l after recurrent measurements with 8 weeks intervals before pregnancy
•6) Positive test for HIV or tests suggestive på hepatitis B or C carrier state.
•7) Psoriasis, retinopathy and adverse hearing loss (contra indications for Plaquenil)
•8) Chronical diseases requiring anti inflammatory medicine or medicine potentially harmfull to pregnancy: corticosteroids, acetylsalicyle acid, indometacin, simvastatin, imurel ect.. Periodic paracetamol use is allowed.
•9) >1 previous live birth
•10) Previous participation in the study

发起方

Henriette Svarre Nielsen